Form 4: BioXcel CFO Richard Steinhart Exercises RSU Grant

Sentiment:

Statement of Changes in Beneficial Ownership


BioXcel Therapeutics CFO Richard Steinhart acquired 9,000 shares of common stock following the vesting of restricted stock units.

Summary

  • CFO Richard Steinhart acquired 9,000 shares of BioXcel Therapeutics common stock on May 1, 2026.
  • The acquisition resulted from the vesting of 9,000 Restricted Stock Units (RSUs) granted on August 1, 2025.
  • Following this transaction, the reporting person holds a total of 15,645 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard executive equity compensation.

Positives

  • The transaction reflects the fulfillment of equity-based compensation incentives for the Chief Financial Officer.

Negatives

  • None identified.

Risks

  • Continued employment requirements for equity vesting.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of executive compensation vesting, common in the biotechnology sector to align management interests with long-term shareholder value.

Comparison to Industry Standards

  • The vesting schedule and equity compensation structure are consistent with standard executive compensation practices for mid-cap biotechnology firms.

Stakeholder Impact

  • Minimal impact on shareholders as this represents standard compensation vesting.

Next Steps

  • None mentioned.

Key Dates

DateDescription
08/01/2025Grant date of the Restricted Stock Units.
05/01/2026Transaction date of RSU vesting and share acquisition.
05/07/2026Date of filing.

Keywords

BioXcel Therapeutics, BTAI, Insider Trading, Form 4, CFO, Equity Compensation

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.